All In Biotech

Drug Trial Radar · NCT02154490

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Last checked: Nov 20, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,864

Actual

Start

Jul 8, 2014

Primary completion

Apr 1, 2022

Study completion Apr 15, 2022

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jun 3, 2014

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

Conditions

  • Recurrent Squamous Cell Lung Carcinoma
  • Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

  • DocetaxelDrug

    Given IV

  • DurvalumabBiological

    Given IV

  • Erlotinib HydrochlorideDrug

    Given PO

  • FGFR Inhibitor AZD4547Drug

    Given PO

  • IpilimumabBiological

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • NivolumabBiological

    Given IV

  • PalbociclibDrug

    Given PO

  • Pharmacological StudyOther

    Correlative studies

  • RilotumumabBiological

    Given IV

  • TalazoparibDrug

    Given PO

  • TaselisibDrug

    Given PO

  • TremelimumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Screen Success RateTime frame: From date of registration to pre-screening or screening component until sub-study registration or death, a median of 3.5 months (IQR 2.0-6.0) in the pre-screened group and 0.9 months (IQR 0.7-1.1) in the screened at progression group.

Locations

1,004 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • The University of Arizona Medical Center-University Campus

    Tucson, Arizona

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Fowler Family Center for Cancer Care

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • City of Hope Corona

    Corona, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Washington Hospital

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Saint Jude Medical Center

    Fullerton, California

  • Kaiser Permanente - Harbor City

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • City of Hope Antelope Valley

    Lancaster, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente-Cadillac

    Los Angeles, California

Showing 40 of 1,004 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.